• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

    2/21/24 5:00:19 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HLTH alert in real time by email
    SC 13D/A 1 p24-0922sc13da.htm CUE HEALTH INC.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Cue Health Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)
     

    229790100

    (CUSIP Number)
     

    Tarsadia Investments, LLC
    520 Newport Center Drive, 21st Floor
    Newport Beach, CA 92660

     

    Tarsadia Capital, LLC

    712 Fifth Avenue, Suite 32D

    New York, NY 10019

     

    T-Twelve Holdings, LLC

    c/o Sierra Fiduciary Support Services

    100 West Liberty St., Suite 750

    Reno, NV 89501

     

    with a copy to:

    Eleazer Klein, Esq.

    Adriana Schwartz, Esq.

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    February 16, 2024

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

    (Page 1 of 17 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 229790100Schedule 13D/APage 2 of 17 Pages

     

    1

    NAME OF REPORTING PERSON

    TCCS I, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    10,684,791

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    10,684,791

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,684,791

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.9%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 229790100Schedule 13D/APage 3 of 17 Pages

     

    1

    NAME OF REPORTING PERSON

    TC GP, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    10,684,791

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    10,684,791

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,684,791

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.9%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 229790100Schedule 13D/APage 4 of 17 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Tarsadia Capital, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    10,684,791

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    10,684,791

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,684,791

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.9%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 229790100Schedule 13D/APage 5 of 17 Pages

     

     

    1

    NAME OF REPORTING PERSON

    NVGA I, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    3,230,779

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    3,230,779

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,230,779

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    2.1%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 229790100Schedule 13D/APage 6 of 17 Pages

     

    1

    NAME OF REPORTING PERSON

    CP (HLTH), LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    3,612,913

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    3,612,913

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,612,913

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    2.4%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 229790100Schedule 13D/APage 7 of 17 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Tarsadia Investments, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    California

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    6,843,692

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    6,843,692

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    6,843,692

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    4.4%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 229790100Schedule 13D/APage 8 of 17 Pages

     

     

    1

    NAME OF REPORTING PERSON

    TUP Investments, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    California

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    1,068,174

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    1,068,174

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    1,068,174

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.7%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

    CUSIP No. 229790100Schedule 13D/APage 9 of 17 Pages

     

    1

    NAME OF REPORTING PERSON

    T-Twelve Holdings, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Nevada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    3,319,000

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    3,319,000

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,319,000

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    2.2%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 229790100Schedule 13D/APage 10 of 17 Pages

     

     

    1

    NAME OF REPORTING PERSON

    TFC Manager, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Nevada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    3,319,000

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    3,319,000

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,319,000

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    2.2%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 229790100Schedule 13D/APage 11 of 17 Pages

     

    1

    NAME OF REPORTING PERSON

    Rishy Reddy

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ý

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    72,573 (including 63,300 Shares underlying restricted stock units)

    8

    SHARED VOTING POWER

    -0-

    9

    SOLE DISPOSITIVE POWER

    72,573 (including 63,300 Shares underlying restricted stock units)

    10

    SHARED DISPOSITIVE POWER

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    72,573 (including 63,300 Shares underlying restricted stock units)

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.1%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 229790100Schedule 13D/APage 12 of 17 Pages

      

    This Amendment No. 2 (“Amendment No. 2”) amends and supplements the statement on Schedule 13D filed by the undersigned on September 11, 2023 (the “Original Schedule 13D”), as amended by Amendment No. 1 filed on September 15, 2023 (“Amendment No. 1” and, together with this Amendment No. 2, the “Schedule 13D”) as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.

     

    Item 2. IDENTITY AND BACKGROUND
       
      Item 2 is hereby amended and restated as follows:
       
    (a) This statement is being filed by:

     

      i. TCCS I, LP, a Delaware limited partnership (“TCCS”), with respect to the Shares held by it;
       
      ii. TC GP, LLC, a Delaware limited liability company (“TC GP”), as the general partner of TCCS, with respect to the Shares held by TCCS;
         
      iii. Tarsadia Capital, LLC, a Delaware limited liability company (“Tarsadia Capital”), as the investment manager of TCCS, with respect to the Shares held by TCCS;
       
      iv. NVGA I, LLC, a Delaware limited liability company (“NVGA”), with respect to the Shares held by it;
         
      v. CP (HLTH), LLC, a Delaware limited liability company (“CP HLTH”), with respect to the Shares held by it;
       
      vi. Tarsadia Investments LLC, a California limited liability company (“Tarsadia Investments”), as the investment manager of each of NVGA and CP HLTH, with respect to the Shares held by each of them;
       
      vii. TUP Investments, L.P., a California limited partnership (“TUP Investments”, together with TCCS, TC GP, Tarsadia Capital, NVGA, CP HLTH and Tarsadia Investments, the “Tarsadia Reporting Persons”), with respect to the Shares held by it;
       
      viii. T-Twelve Holdings, LLC, a Nevada limited liability company (“T-Twelve Holdings”), with respect to the Shares held by it;
         
      ix. TFC Manager, LLC, a Nevada limited liability company (“TFC Manager”, and together with T-Twelve Holdings, the “T-Twelve Reporting Persons”), as the manager of T-Twelve Holdings, with respect to the Shares held by T-Twelve Holdings; and
         
      x. Mr. Rishi Reddy (“Mr. Reddy”) with respect to the Shares and the Shares issuable upon vesting of restricted stock units held by him.

     

      Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”
       
      Tushar Patel, a United States citizen (the “Tarsadia Principal”), is the ultimate control person of each of the Tarsadia Reporting Persons.

     

    CUSIP No. 229790100Schedule 13D/APage 13 of 17 Pages

      

      Akram Mahesh, a United States citizen (the “T-Twelve Principal”), is the ultimate control person of each of the T-Twelve Reporting Persons.
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

    (b) The principal business address of:

     

      i. Each of TCCS, TC GP and Tarsadia Capital is 712 Fifth Avenue, Suite 32D, New York, NY 10019;
       
      ii. Each of NVGA, CP HLTH, TUP Investments, Tarsadia Investments and the Tarsadia Principal is 520 Newport Center Dr., 21st Floor, Newport Beach, CA 92660;
         
      iii. Each of T-Twelve Holdings, TFC Manager and the T-Twelve Principal is c/o Sierra Fiduciary Support Services, 100 West Liberty St., Suite 750, Reno, NV 89501; and
         
      iv. Mr. Reddy is c/o Tarsadia Investments, LLC 520 Newport Center Dr., 21st Floor, Newport Beach, CA 92660.

     

    (c) The principal business of:

     

      i. Each of TCCS, NVGA, CP HLTH, TUP Investments and T-Twelve Holdings is to serve as a private investment vehicle for the owners thereof;
       
      ii. TC GP is to serve as the general partner of TCCS;
       
      iii. Tarsadia Capital, which is part of a single-family office that, together with Tarsadia Investments and one or more of their respective affiliates, is to provide investment management services to TCCS and other private investment vehicles, in each case, for the owners thereof;
       
      iv. Tarsadia Investments, which is part of a single-family office that, together with Tarsadia Capital and one or more of their respective affiliates, is to provide investment management services to NVGA and CP HLTH, and other private investment vehicles, in each case for the owners thereof;
       
      v. TFC Manager is to serve as the manager of T-Twelve Holdings;
       
      vi. The Tarsadia Principal is as Chairman and Founder of the Tarsadia family office;
       
      vii. The T-Twelve Principal is to serve as an Analytics Advisor at a global health company; and
         
      viii. Mr. Reddy is Head of Venture and Growth Equity Investing at Tarsadia Investments.

     

     

    CUSIP No. 229790100Schedule 13D/APage 14 of 17 Pages

      

    (d) During the last five years, none of the Reporting Persons, the Tarsadia Principal or the T-Twelve Principal has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
       
    (e) During the last five years, none of the Reporting Persons, the Tarsadia Principal or the T-Twelve Principal has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
       
    (f) i. TCCS is a Delaware limited partnership;
         
      ii. Each of TC GP and Tarsadia Capital is a Delaware limited liability company;
         
      iii. NVGA is a Delaware limited liability company;
         
      iv. CP HLTH is a Delaware limited liability company;
         
      v. Tarsadia Investments is a California limited liability company;
         
      vi. TUP Investments is a California limited partnership;
         
      vii. Each of T-Twelve Holdings and TFC Manager is a Nevada limited liability company; and
         
      viii. Each of the Tarsadia Principal, the T-Twelve Principal and Mr. Reddy is a citizen of the United States of America.

     

    Item 4. PURPOSE OF TRANSACTION
       
      Item 4 is hereby amended and supplemented by the addition of the following:
       
      On February 16, 2024, each of the Reporting Persons entered into a Cooperation Agreement with the Issuer (the “Cooperation Agreement”), pursuant to which, among other things, the Issuer has agreed to increase the size of the Issuer’s board of Directors (the “Board”) and appoint Mr. Reddy as a Class I director, effective immediately, with a term expiring at the Issuer’s 2025 annual meeting of stockholders. Concurrent with his appointment to the Board, Mr. Reddy was appointed to serve on the Nominating and Corporate Governance Committee of the Board. The Company will cooperate in good faith with the Reporting Persons to mutually agree upon an additional individual to serve as an independent director on the Board.
       
      The Cooperation Agreement also provides for customary standstill provisions during the Restricted Period (as defined of the Cooperation Agreement), including, among other things, a restriction on the ability of the Reporting Persons to increase their  beneficial ownership of the Issuer’s Shares.
       
      The Cooperation Agreement also provides that during the Restricted Period, the Reporting Persons will vote, subject to certain limited exceptions, their Shares, at each stockholder meeting, in accordance with the recommendation of the Board.

     

    CUSIP No. 229790100Schedule 13D/APage 15 of 17 Pages

      

      The foregoing description of the Cooperation Agreement is not complete and is qualified in its entirety by the full text of the Cooperation Agreement which is attached hereto as Exhibit 99.3.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
      Item 5(a) is hereby amended and restated as follows:
       
      (a)  See rows (11) and (13) of each of the cover pages to this Schedule 13D for the number of Shares and percentage of the Shares beneficially owned by each of the Reporting Persons. The percentage of Shares reported beneficially owned by the Reporting Persons is based upon 154,632,057 Shares outstanding as of November 1, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2023.
       
      As disclosed in Item 4, as of August 31, 2023, the Tarsadia Reporting Persons and the T-Twelve Reporting Persons have determined to work together in furtherance of the objectives set forth in the August 31 Press Release and the Cooperation Agreement. Accordingly, the Reporting Persons may be deemed to have formed a “group” within the meaning of Section 13(d)(3) of the Exchange Act and the “group” may be deemed to beneficially own an aggregate of 21,988,230 Shares, representing approximately 14.21% of the outstanding Shares. Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares beneficially owned by the other Reporting Persons.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       
      Item 6 is hereby amended and supplemented by the addition of the following:
       
       Item 4 of this Amendment No. 2 is hereby incorporated by reference herein.
       
      On February 16, 2024, Mr. Reddy was granted a total of 63,300 restricted stock units in consideration for his service on the Board. The restricted stock units will vest in full on June 5, 2024, subject to Mr. Reddy’s continued service as a director.
       
      Except as otherwise set forth herein, and the joint filing agreement attached hereto as Exhibit 99.4, the Reporting Persons have no contracts, arrangements, understandings or relationships with any person with respect to the securities of the Issuer.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS
       
    Exhibit 99.3: Cooperation Agreement, dated February 16, 2024 (incorporated by reference to Exhibit 10.1 of the Issuer’s Form 8-K, filed with the SEC on February 16, 2024).
       
    Exhibit 99.4 Joint Filing Agreement, dated February 21, 2024.
       

     

    CUSIP No. 229790100Schedule 13D/APage 16 of 17 Pages

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATE: February 21, 2024

      TCCS I, LP
      By: TC GP, LLC, its General Partner
       
       
      /s/ Vikram Patel
      Name: Vikram Patel
      Title: Authorized Signatory

     

      TC GP, LLC
       
       
      /s/ Vikram Patel
      Name: Vikram Patel
      Title: Authorized Signatory

     

      Tarsadia Capital, LLC
       
       
      /s/ Vikram Patel
      Name: Vikram Patel
      Title: Head of Tarsadia Capital, LLC

     

      NVGA I, LLC
      By: TI Manager, LLC, its Manager
       
       
      /s/ Vikram Patel
      Name: Vikram Patel
      Title: Managing Director

     

      CP (HLTH), LLC
      By: TI Manager, LLC, its Manager
       
       
      /s/ Vikram Patel
      Name: Vikram Patel
      Title: Managing Director

     

     

    CUSIP No. 229790100Schedule 13D/APage 17 of 17 Pages

      

      Tarsadia Investments, LLC
       
       
      /s/ Mitchell Caplan
      Name: Mitchell Caplan
      Title: President

     

      TUP Investments, L.P.
      By: TUP Three, LLC, its General Partner
       
       
      /s/ Vikram Patel
      Name: Vikram Patel
      Title: Manager

     

     

    T-Twelve Holdings, LLC

    By: TFC Manager, LLC, its Manager

       
       
      /s/ John Galvin
      Name: John Galvin
      Title: Manager

     

      TFC Manager, LLC
       
       
      /s/ John Galvin
      Name: John Galvin
      Title: Manager
       
       
      /s/ Rishy Reddy
      RISHY REDDY

     

     

     

     

     

    Get the next $HLTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLTH

    DatePrice TargetRatingAnalyst
    3/14/2024Buy → Neutral
    BTIG Research
    10/19/2021$18.00Buy
    BTIG Research
    10/19/2021$12.00Equal-Weight
    Morgan Stanley
    10/19/2021$19.00Buy
    Goldman Sachs
    10/19/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Javed Aasim covered exercise/tax liability with 13,327 shares, decreasing direct ownership by 1% to 998,004 units (SEC Form 4) (Amendment)

      4/A - Cue Health Inc. (0001628945) (Issuer)

      5/21/24 6:29:25 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sever Clint covered exercise/tax liability with 20,456 shares, decreasing direct ownership by 0.46% to 4,379,914 units (SEC Form 4)

      4 - Cue Health Inc. (0001628945) (Issuer)

      3/27/24 7:29:01 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pollard Randall E. covered exercise/tax liability with 7,304 shares, decreasing direct ownership by 1% to 503,202 units (SEC Form 4)

      4 - Cue Health Inc. (0001628945) (Issuer)

      3/7/24 8:45:08 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Financials

    Live finance-specific insights

    See more
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Reports Fourth Quarter 2023 Financial Results

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24 Executed cost reduction plans, resulting in cash

      3/13/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed by visiting the Events

      2/28/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    SEC Filings

    See more

    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $HLTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Cue Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Cue Health Inc. (0001628945) (Filer)

      5/28/24 5:02:54 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Cue Health Inc. (0001628945) (Filer)

      5/16/24 4:20:43 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form NT 10-Q filed by Cue Health Inc.

      NT 10-Q - Cue Health Inc. (0001628945) (Filer)

      5/16/24 4:17:26 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

      SC 13D/A - Cue Health Inc. (0001628945) (Subject)

      5/17/24 3:21:32 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

      SC 13D/A - Cue Health Inc. (0001628945) (Subject)

      2/21/24 5:00:19 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cue Health Inc. (Amendment)

      SC 13G/A - Cue Health Inc. (0001628945) (Subject)

      2/14/24 5:09:58 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Pursue Wind Down of the Business

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process to locate additional financing or effect a strategic transaction. Despite its best efforts and after a comprehensive review, Cue's Board of Directors in consultation with the Company's advisors, has concluded that it is in the b

      5/28/24 4:31:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

      Cue Health Inc. (NASDAQ:HLTH), a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days. About Cue Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-based care with fast, highly accurate test results on demand. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive t

      5/13/24 8:30:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health downgraded by BTIG Research

      BTIG Research downgraded Cue Health from Buy to Neutral

      3/14/24 7:38:37 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • BTIG Research initiated coverage on Cue Health with a new price target

      BTIG Research initiated coverage of Cue Health with a rating of Buy and set a new price target of $18.00

      10/19/21 9:45:18 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley initiated coverage on Cue Health with a new price target

      Morgan Stanley initiated coverage of Cue Health with a rating of Equal-Weight and set a new price target of $12.00

      10/19/21 8:30:49 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Strategic Actions to Position Company for Next Stage

      Clint Sever Appointed CEO Board Appoints Two Strategic Advisors Who Bring Significant Industry Expertise Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the "Board") to best position the Company for its next stage: Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as Chief Executive Officer, President, and Chairman. Khattak will remain a member of the Board of Directors. The Board has appointed two strategic advisors, who have specific subject matter expertise in i

      3/20/24 5:21:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Appointment of Rishi Reddy to Board of Directors

      Cue Health (NASDAQ:HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the "Cooperation Agreement") with Tarsadia Investments ("Tarsadia"), and appointed Rishi Reddy to its board of directors (the "Board"), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm's venture and growth equity strategy. He was previously an Observer on Cue's Board of Directors from April 2018 to September 2021. In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board. "Cue remains focused on creating value for all of its stakeholders," said Ayub Khattak, Chairm

      2/16/24 5:00:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D. to its Board of Directors

      Cue Health ("Cue") (NASDAQ:HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D. have joined its Board of Directors. Cue Health's Board now consists of seven directors, five of whom are independent. "On behalf of the management team and Board, I'm pleased to welcome both Josh and Sachin to the Cue team. We are excited to have vast knowledge of health plans and payors as well as the perspective of a medical doctor on Cue's Board as we continue to pursue our vision of making healthcare more convenient, accessible, and timely by placing diagnostic information at the center of care," said Ayub

      11/17/22 4:15:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

      For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

      6/6/23 3:04:14 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials